DHC Stock — Diversified Healthcare Trust

Up next

Next earnings call

Nov 3, 2026 Est · unconfirmed · in 7 wks

Latest filing: 10-Q

filed Aug 3, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$1.50B

Trailing 12 months

Net income (TTM)

−$265.95M

Trailing 12 months

Revenue growth YoY

-4.5%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+0.3%

Year over year · more shares

Price change (1Y)

+72.6%

Trailing year

Short interest

5.3%

Latest settlement · 11.5 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 4, 2026

Q2 FY26

TL;DR. DHC reported strong Q2 results with 37.2% YoY same-property SHOP NOI growth and reaffirmed recently raised full-year guidance, while reducing 2026 SHOP occupancy and revenue growth assumptions (offset by improved expense control) and announcing new operator contracts set to begin January 2027.

Bullish

+ Same-property SHOP NOI grew 37.2% YoY to $52 million with margins expanding 390 bps to 17.3%.
+ Medical office leasing was robust with 477,000 sq ft at 6.7% rent roll-up and 7.1-year weighted average lease term.
+ Full-year 2026 guidance was reaffirmed at raised levels, with SHOP NOI tracking toward high end.

Bearish

− SHOP top-line pacing below initial 2026 projections with occupancy gains slower than expected.
− Q2 shop same-store NOI included a ~$1.5 million one-time expense benefit not expected to repeat.
− Three known MOB/life science tenant vacates representing ~4.6% of segment annualized revenue, with two effective July 1.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Research

our published analysis of this company

Research Thesis July 14, 2026

Alexandria Real Estate Equities: stress event priced in, dividend reset is the test

Alexandria Real Estate Equities sits at a -38.8% trailing-twelve-month change and a -45.0% drawdown from its 52-week high after cutting its dividend from $1.32 to $0.72 and reporting zero public biotech leasing for the first quarter in company history. The peer office REIT cohort is reporting tightening markets and raising FFO midpoints, leaving ARE's stress specific to its public-biotech exposure — the setup turns on whether the 1.1 million square feet of leased vacant space delivers in September 2026, the $2.2 billion disposition program closes on pace, and public biotech leasing returns in Q2.

Equibles Rating

blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Moderate

Market backdrop VIX 17.1 · elevated Equity put/call 0.67

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +5%

above

Price vs 50-day avg −9%

below

RSI (14) 40

neutral

MACD trend Positive

52-week position 65%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −8%

trailing

6-month return +15%

trailing

YTD return +58%

this year

Relative strength −1%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $8 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+4% holders QoQ · +42 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

5.34% of float · ▼ -2.2% MoM · 11.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

240 holders — near 3-yr high, broad support

Squeeze score 61

elevated · 0–100

Fundamentals

Fair

Revenue growth +2%

Y/Y

EPS growth +23%

Y/Y

Balance sheet $2.3B

net debt

Quant / Vol

risk profile

Moderate

Volatility 39%

annualized · 1-yr

Max drawdown −22%

past year

ATR 3.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the Earnings Call filed Jun 30, 2026

full-year 2026

Total NOI Initiated $307M – $323M

SHOP NOI Initiated $185M – $195M

Adjusted EBITDAre Non-GAAP Initiated $300M – $315M

Normalized FFO per share Non-GAAP Initiated $0.56 – $0.62

full year

Normalized FFO Non-GAAP $0.56 – $0.62

Adjusted EBITDA RE Non-GAAP $300M – $315M

SHOP revenue growth 6.6%

Average monthly rate growth 5.5%

SHOP operating expense growth 2.5%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 2

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+5% Bullish

Price vs 50-day avg

−9% Bearish

RSI (14)

40 Neutral

MACD trend

Positive Bullish

52-week position

65% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $8 › 200d $7 — 50d above 200d

Institutional flow Accumulating

+4% holders QoQ · +42 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

5.34% of float · ▼ -2.2% MoM · 11.5 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

240 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $4 Now $8 · 65% Range high $10

vs 200-day avg +5% vs 50-day avg -9%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

REIT - Healthcare Facilities — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
DHC Diversified Healthcare Trust this stock	$1.86B	+58.4%	+1.6%	—	5.3%
WELL Welltower Inc.	$164.51B	+26.2%	+35.6%	115.9	2.6%
VTR Ventas, Inc.	$45.31B	+15.1%	+18.5%	163.6	4.0%
OHI Omega Healthcare Investors Inc	$14.34B	+6.8%	+13.2%	16.9	4.3%
DOC Healthpeak Properties, Inc.	$14.05B	+26.7%	+4.5%	58.2	3.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

240

% held: 85.3%
Net QoQ: +19.3M sh
Top holder: Flat Footed LLC

Held Float

View

Held by Funds

Fund positions

211

View

Short & Settlement

Short Interest Falling

Shares short

12.9M

Days to cover: 11.5d
Change: -295.9K sh

View

Short Volume

Short vol %

49%

As of: Sep 14, 2026

Short Total

View

Fails to Deliver

FTD shares

86

Value: $695
As of: Aug 26, 2026

View

Off-Exchange

Off-exchange %

42.4%

Week of: Aug 10, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$1.5B

Net income (FY): $-285.9M
EPS diluted: $-1.19

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 3, 2026
This year: 13

View

Earnings & Events

Earnings Calls

Last call

Aug 4, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
DHC	+2.3%	-8.4%	+14.6%	+1.5%	+58.4%
SPY	-1.2%	-2.0%	+16.1%	-0.8%	+11.6%
vs SPY	+3.5%	-6.4%	-1.5%	+2.3%	+46.8%

DHC · Diversified Healthcare Trust

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Research

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance